On June 10, 2021, the Board of Directors of Mosaic ImmunoEngineering Inc. approved that the number of directors be increased from six (6) to seven (7) members and also recommended that stockholders elect Dr. Robert A. Baffi to its Board of Directors and as a member of the Audit Committee and Corporate Governance and Nominating Committee of the Board. On June 14, 2021, the Majority Stockholders, representing 80% of the outstanding voting power of the Company, elected Dr. Baffi to serve as director with such terms to begin no sooner than the 20 calendar day after the date on which the Information Statement and the accompanying notice are mailed to stockholders (the "Effective Date").